GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modern Chinese Medicine Group Co Ltd (HKSE:01643) » Definitions » Peter Lynch Fair Value

Modern Chinese Medicine Group Co (HKSE:01643) Peter Lynch Fair Value : HK$0.71 (As of Jun. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Modern Chinese Medicine Group Co Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Modern Chinese Medicine Group Co's PEG is 1. Modern Chinese Medicine Group Co's 5-Year TTM EBITDA Growth Rate is 8.03. Modern Chinese Medicine Group Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.09. Therefore, the Peter Lynch Fair Value for today is HK$0.71.

As of today (2024-06-08), Modern Chinese Medicine Group Co's share price is HK$0.375. Modern Chinese Medicine Group Co's Peter Lynch fair value is HK$0.71. Therefore, Modern Chinese Medicine Group Co's Price to Peter Lynch Fair Value Ratio for today is 0.52.


The historical rank and industry rank for Modern Chinese Medicine Group Co's Peter Lynch Fair Value or its related term are showing as below:

HKSE:01643' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.13   Med: 0.31   Max: 0.53
Current: 0.53


During the past 7 years, the highest Price to Peter Lynch Fair Value Ratio of Modern Chinese Medicine Group Co was 0.53. The lowest was 0.13. And the median was 0.31.


HKSE:01643's Price-to-Peter-Lynch-Fair-Value is ranked better than
86.46% of 288 companies
in the Drug Manufacturers industry
Industry Median: 1.32 vs HKSE:01643: 0.53

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Modern Chinese Medicine Group Co Peter Lynch Fair Value Historical Data

The historical data trend for Modern Chinese Medicine Group Co's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modern Chinese Medicine Group Co Peter Lynch Fair Value Chart

Modern Chinese Medicine Group Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - 4.08 0.71

Modern Chinese Medicine Group Co Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - 4.08 - 0.71

Competitive Comparison of Modern Chinese Medicine Group Co's Peter Lynch Fair Value

For the Drug Manufacturers - General subindustry, Modern Chinese Medicine Group Co's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modern Chinese Medicine Group Co's Price-to-Peter-Lynch-Fair-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modern Chinese Medicine Group Co's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Modern Chinese Medicine Group Co's Price-to-Peter-Lynch-Fair-Value falls into.



Modern Chinese Medicine Group Co Peter Lynch Fair Value Calculation

Modern Chinese Medicine Group Co's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 8.03 *0.089
=0.71

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Modern Chinese Medicine Group Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.09.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Modern Chinese Medicine Group Co  (HKSE:01643) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 8.03 instead of 15 in this case.

Modern Chinese Medicine Group Co's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.375/0.71
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Modern Chinese Medicine Group Co Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Modern Chinese Medicine Group Co's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Modern Chinese Medicine Group Co (HKSE:01643) Business Description

Traded in Other Exchanges
N/A
Address
No. 88 Jinwei Road, Hebei, Chengde, CHN, 068150
Modern Chinese Medicine Group Co Ltd is engaged in the production of proprietary Chinese medicine. It offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. Its products include Vigour and Vitality Supplement Pill, Circulation Enhancement Pill, Cardiotonic Enhancement Capsule, Kidney Invigoration Pill, Heart Wellness Capsule, Menstrual Discomfort Relief Pill, Liver Detox Tablet, and Additional Ingredient Huoxiang ZhengQi Pill and Fever-removing and Detoxification Pill. The Group has one operating segment of its business as a whole as the production of PCM. Geographically, the majority is from PRC.
Executives
Sun Xinlei 2201 Interest of corporation controlled by you
Xian Dai Sheng Wu Ke Ji Ji Tuan Kong Gu You Xian Gong Si 2101 Beneficial owner
Xie Wei 2201 Interest of corporation controlled by you

Modern Chinese Medicine Group Co (HKSE:01643) Headlines

No Headlines